Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31555114 | 1.00 | CHRM2 (0.49) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL22674240 | 0.95 | SIGMAR1 (0.52) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL256358 | 0.89 | CYP3A4 (0.46) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL31518333 | 0.89 | CYP3A4 (0.46) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL16998410 | 0.85 | SIGMAR1 (0.48) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL22674242 | 0.80 | SIGMAR1 (0.52) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL22313609 | 0.78 | CHRM2 (0.49) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL14494879 | 0.77 | CHRM2 (0.46) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL13180255 | 0.77 | CHRM2 (0.59) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 | |
| SCHEMBL13145763 | 0.77 | CHRM2 (0.46) | CHRM2CHRM3CHRM1SIGMAR1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | BOSTON BIOMEDICAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | BOSTON BIOMEDICAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170174646-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BOSTON BIOMEDICAL, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174646-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BOSTON BIOMEDICAL, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2015120304-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BOSTON BIOMEDICAL, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2009147476-A1 | NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | MATRIX LABORATORIES LTD. (IN) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CHRM2 4704/4885CHRM3 4601/4885CHRM1 4726/4885 |
| US-20170174646-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | FGFR3, FGFR1, FGF2 | CHRM2 4064/4885CHRM3 4255/4885CHRM1 3262/4885 |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | FGFR3, FGFR1, FGF2 | CHRM2 4064/4885CHRM3 4255/4885CHRM1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.